Evidence of Prognostic Relevant Expression Profiles of Heat-Shock Proteins and Glucose-Regulated Proteins in Oesophageal Adenocarcinomas
暂无分享,去创建一个
R. Langer | M. Feith | H. Höfler | A. Walch | J. Slotta-Huspenina | K. Becker | E. Drecoll | M. Bettstetter | D. Berg | K. Malinowsky | C. Wolff | Karina Bauer | L. Bauer
[1] Helen M. Moore,et al. Biospecimen Reporting for Improved Study Quality (BRISQ) , 2013, Transfusion.
[2] C. Garrido,et al. Targeting heat shock proteins in cancer. , 2013, Cancer letters.
[3] Michael Riffle,et al. A Mass Spectrometry Proteomics Data Management Platform* , 2012, Molecular & Cellular Proteomics.
[4] R. Langer,et al. High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer , 2012, Cellular Oncology.
[5] S. Deraz,et al. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? , 2011, Biochimica et biophysica acta.
[6] G. Murray,et al. The Proteomics of Colorectal Cancer: Identification of a Protein Signature Associated with Prognosis , 2011, PloS one.
[7] R. Hendrickson,et al. Identification of Direct Target Engagement Biomarkers for Kinase-Targeted Therapeutics , 2011, PloS one.
[8] R. Langer,et al. Discovery of New Molecular Subtypes in Oesophageal Adenocarcinoma , 2011, PloS one.
[9] K. Coombes,et al. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer , 2011, Clinical Proteomics.
[10] K. Janda,et al. Inducing apoptosis in chemotherapy‐resistant B‐lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti‐apoptotic unfolded protein response signalling network , 2011, British journal of haematology.
[11] R. Klopfleisch,et al. Excavation of a buried treasure--DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues. , 2011, Histology and histopathology.
[12] R. Langer,et al. Significance of Histopathological Tumor Regression After Neoadjuvant Chemotherapy in Gastric Adenocarcinomas: A Summary of 480 Cases , 2011, Annals of surgery.
[13] Helen M. Moore,et al. Biospecimen Reporting for Improved Study Quality. , 2011, Biopreservation and biobanking.
[14] H. Matsubara,et al. Correlation Between gp96 Expression and the Surgical Outcome in Patients With Esophageal Squamous Cell Carcinoma , 2011, Annals of Surgical Oncology.
[15] E. Benarroch. Heat shock proteins , 2011, Neurology.
[16] K. Becker,et al. Successful Protein Extraction from Over-Fixed and Long-Term Stored Formalin-Fixed Tissues , 2011, PloS one.
[17] H. Höfler,et al. Signalling networks associated with urokinase‐type plasminogen activator (uPA) and its inhibitor PAI‐1 in breast cancer tissues: new insights from protein microarray analysis , 2011, The Journal of pathology.
[18] J. Edwards,et al. GRP78 up‐regulation is associated with androgen receptor status, Hsp70–Hsp90 client proteins and castrate‐resistant prostate cancer , 2011, The Journal of pathology.
[19] K. Coombes,et al. Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] G. Chiosis,et al. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1 , 2010, Journal of hematology & oncology.
[21] H. Grabsch,et al. Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer , 2010, Gut.
[22] Caterina Barillari,et al. Targeting HSP70: The second potentially druggable heat shock protein and molecular chaperone? , 2010, Cell cycle.
[23] C. Hunt,et al. Geldanamycin and its anti-cancer activities. , 2010, Cancer letters.
[24] Xiaoping Wang,et al. Correlation between Clinicopathology and Expression of Heat Shock Protein 72 and Glycoprotein 96 in Human Esophageal Squamous Cell Carcinoma , 2010, Clinical & developmental immunology.
[25] R. Langer,et al. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas , 2009, Modern Pathology.
[26] P. Workman,et al. Death by chaperone: HSP90, HSP70 or both? , 2009, Cell cycle.
[27] M. Bergqvist,et al. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin , 2009, British Journal of Cancer.
[28] U. Banerji,et al. Heat Shock Protein 90 as a Drug Target: Some Like It Hot , 2009, Clinical Cancer Research.
[29] R. Langer,et al. Protein Expression Profiling in Esophageal Adenocarcinoma Patients Indicates Association of Heat-Shock Protein 27 Expression and Chemotherapy Response , 2008, Clinical Cancer Research.
[30] M. Bergqvist,et al. 154 POSTER Hsp90 is expressed and represents a novel target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxy- geldanamycin , 2008 .
[31] Helen M. Moore,et al. Documenting biospecimen conditions in reports of studies. , 2008, JAMA.
[32] R. Langer,et al. Expression and clinical significance of Glucose Regulated Proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus , 2008, BMC Cancer.
[33] L. Freitag,et al. Patient survival by Hsp70 membrane phenotype , 2007, Cancer.
[34] Amy S. Lee. GRP78 induction in cancer: therapeutic and prognostic implications. , 2007, Cancer research.
[35] D. Parmar,et al. Proteomics in clinical interventions: achievements and limitations in biomarker development. , 2007, Life sciences.
[36] J. Nährig,et al. Quantitative protein analysis from formalin‐fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis , 2007, The Journal of pathology.
[37] G. Mills,et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.
[38] J. Reitsma,et al. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] C. V. D. van de Velde,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.
[40] Amy S. Lee,et al. Glucose regulated proteins in cancer progression, Drug resistance and immunotherapy , 2006, Cancer biology & therapy.
[41] C. Gulmann,et al. Array‐based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer , 2006, The Journal of pathology.
[42] D. Sawyer,et al. Heat shock proteins in cancer: chaperones of tumorigenesis. , 2006, Trends in biochemical sciences.
[43] S. Baldus,et al. Histomorphologic Tumor Regression and Lymph Node Metastases Determine Prognosis Following Neoadjuvant Radiochemotherapy for Esophageal Cancer: Implications for Response Classification , 2005, Annals of surgery.
[44] Seung-Oe Lim,et al. Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. , 2005, World journal of gastroenterology.
[45] F. Lordick,et al. Neoadjuvant therapy for oesophagogastric cancer , 2004, The British journal of surgery.
[46] H. Höfler,et al. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. , 2001, The American journal of pathology.
[47] H. Höfler,et al. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility , 1999, Oncogene.
[48] Johannes Buchner,et al. Regulation of Hsp27 Oligomerization, Chaperone Function, and Protective Activity against Oxidative Stress/Tumor Necrosis Factor α by Phosphorylation* , 1999, The Journal of Biological Chemistry.
[49] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[50] K. Becker,et al. Producing reverse phase protein microarrays from formalin-fixed tissues. , 2011, Methods in molecular biology.
[51] K. Becker,et al. Use of formalin-fixed and paraffin-embedded tissues for diagnosis and therapy in routine clinical settings. , 2011, Methods in molecular biology.
[52] Daniela Berg,et al. Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues. , 2010, European journal of cancer.
[53] S. Nishizuka,et al. Reverse-phase protein lysate microarrays for cell signaling analysis , 2008, Nature Protocols.
[54] S. DeMeester. Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment , 2006, Annals of Surgical Oncology.
[55] Stuart K. Calderwood,et al. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications , 2005, Cell stress & chaperones.
[56] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.